Valeo Financial Advisors LLC Sells 177 Shares of Glaukos Co. (NYSE:GKOS)

Valeo Financial Advisors LLC lowered its holdings in shares of Glaukos Co. (NYSE:GKOS) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,700 shares of the medical instruments supplier’s stock after selling 177 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Glaukos were worth $1,155,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in GKOS. Values First Advisors Inc. bought a new stake in shares of Glaukos in the 3rd quarter worth about $25,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter worth about $90,000. Harvest Fund Management Co. Ltd lifted its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV lifted its holdings in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares during the last quarter. Finally, EWA LLC bought a new stake in shares of Glaukos in the 3rd quarter worth about $209,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Up 4.6 %

NYSE GKOS opened at $153.06 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of -50.68 and a beta of 1.04. The company’s 50-day simple moving average is $151.66 and its two-hundred day simple moving average is $138.22. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,859,454.08. The trade was a 23.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,328 shares of company stock valued at $2,289,521. Company insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of several analyst reports. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. BTIG Research raised their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $151.08.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.